Cymabay Therapeu Valuation

CBAYDelisted Stock  USD 32.48  0.01  0.03%   
At this time, the firm appears to be overvalued. Cymabay Therapeu shows a prevailing Real Value of $25.48 per share. The current price of the firm is $32.48. Our model approximates the value of Cymabay Therapeu from analyzing the firm fundamentals such as Return On Equity of -0.64, shares outstanding of 114.78 M, and Operating Margin of (745.58) % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and dropping overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Overvalued
Today
32.48
Please note that Cymabay Therapeu's price fluctuation is not too volatile at this time. Calculation of the real value of Cymabay Therapeu is based on 3 months time horizon. Increasing Cymabay Therapeu's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Cymabay Therapeu is useful when determining the fair value of the Cymabay stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Cymabay Therapeu. Since Cymabay Therapeu is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cymabay Stock. However, Cymabay Therapeu's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  32.48 Real  25.48 Hype  32.48 Naive  33.92
The real value of Cymabay Stock, also known as its intrinsic value, is the underlying worth of Cymabay Therapeu Company, which is reflected in its stock price. It is based on Cymabay Therapeu's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Cymabay Therapeu's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cymabay Therapeu's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
25.48
Real Value
35.73
Upside
Estimating the potential upside or downside of Cymabay Therapeu helps investors to forecast how Cymabay stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cymabay Therapeu more accurately as focusing exclusively on Cymabay Therapeu's fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
32.4732.4832.49
Details
Hype
Prediction
LowEstimatedHigh
28.4532.4836.51
Details
Naive
Forecast
LowNext ValueHigh
29.8933.9237.95
Details

Cymabay Therapeu Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Cymabay Therapeu's current stock value. Our valuation model uses many indicators to compare Cymabay Therapeu value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cymabay Therapeu competition to find correlations between indicators driving Cymabay Therapeu's intrinsic value. More Info.
Cymabay Therapeu is rated below average in price to earning category among related companies. It is rated fourth in price to book category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cymabay Therapeu by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cymabay Therapeu's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cymabay Therapeu's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cymabay Therapeu's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cymabay Therapeu and how it compares across the competition.

About Cymabay Therapeu Valuation

The delisted stock valuation mechanism determines the current worth of Cymabay Therapeu on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Cymabay Therapeu. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cymabay Therapeu based exclusively on its fundamental and basic technical indicators. By analyzing Cymabay Therapeu's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Cymabay Therapeu's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cymabay Therapeu. We calculate exposure to Cymabay Therapeu's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cymabay Therapeu's related companies.
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California. Cymabay Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 59 people.

8 Steps to conduct Cymabay Therapeu's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Cymabay Therapeu's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Cymabay Therapeu's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Cymabay Therapeu's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Cymabay Therapeu's revenue streams: Identify Cymabay Therapeu's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Cymabay Therapeu's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Cymabay Therapeu's growth potential: Evaluate Cymabay Therapeu's management, business model, and growth potential.
  • Determine Cymabay Therapeu's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Cymabay Therapeu's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Cymabay Therapeu Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Cymabay Therapeu does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Common Stock Shares Outstanding106.2 M
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
Note that the Cymabay Therapeu information on this page should be used as a complementary analysis to other Cymabay Therapeu's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Other Consideration for investing in Cymabay Stock

If you are still planning to invest in Cymabay Therapeu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Cymabay Therapeu's history and understand the potential risks before investing.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Money Managers
Screen money managers from public funds and ETFs managed around the world
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities